ArticlePLoS computational biology2026
Explainable AI-driven diagnosis model for early glaucoma detection using grey-wolf optimized extreme learning machine approach.
Article in PLoS computational biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is a leading global cause of blindness, making early detection essential. This paper introduces GlaucoXAI (Glaucoma Explainable AI), an advanced computer-aided diagnosis (CAD) model that integrates machine learning and explainable AI for glaucoma detection using retinal fundus images. The proposed model consists of four stages, including preprocessing, feature extraction, dimensionality reduction, and classification. Initially, features are extracted using the fast discrete curvelet transform with wrapping (FDCT-WRP) to obtain curve-type features. During the next stage, principal component analysis (PCA) and linear discriminant analysis (LDA) are combined to reduce the dimensionality of the feature matrix, followed by a classification stage employing an improved grey wolf optimization (IMGWO) with an extreme learning machine (ELM) to optimize the weight and bias to reduce the overfitting of the model. The model has been experimented with two publicly available datasets named G1020 and ORIGA. The model has achieved 93.87% accuracy on G1020 and 95.38% on ORIGA, outperforming existing methods. The 10 × 5-fold stratified cross-validation (SCV) with explainable AI enhances the interpretability of models and improves clinician trust. Overall, the proposed approach offers accurate, efficient, and explainable glaucoma diagnosis, potentially supporting ophthalmologists in early disease detection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.